| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.02▼ | 1.06▼ | 1.07▼ | 1.44▼ | 1.23▼ |
| MA10 | 1.02▼ | 1.09▼ | 1.24▼ | 1.32▼ | 1.23▼ |
| MA20 | 1.06▼ | 1.31▼ | 1.45▼ | 1.29▼ | 1.12▼ |
| MA50 | 1.12▼ | 1.47▼ | 1.38▼ | 1.24▼ | 1.38▼ |
| MA100 | 1.37▼ | 1.37▼ | 1.31▼ | 1.13▼ | 0.94▲ |
| MA200 | 1.51▼ | 1.32▼ | 1.26▼ | 1.36▼ | 1.41▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | -0.026▼ | -0.071▼ | 0.006▲ | 0.018▲ |
| RSI | 29.431▼ | 20.105▼ | 24.643▼ | 40.012▼ | 44.864▼ |
| STOCH | 20.917 | 7.163▼ | 4.132▼ | 64.136 | 64.589 |
| WILL %R | -87.500▼ | -98.473▼ | -98.639▼ | -93.635▼ | -61.162 |
| CCI | -54.920 | -77.660 | -89.645 | -59.216 | 47.960 |
| ▼ RSI | $CGTX RSI(14) Crossed Below 70 | Set Alert |
| RSI | $CGTX RSI(14) Crossed Below 50 | Set Alert |
| MA | $CGTX Price Crossed Below MA(200) | Set Alert |
| MA | $CGTX Price Crossed Below MA(50) | Set Alert |
| MA | $CGTX Price Crossed Below MA(26) | Set Alert |
| MA | $CGTX Price Crossed Below MA(13) | Set Alert |
| MA | $CGTX Price Crossed Below MA(7) | Set Alert |
| ▼ GAP | $CGTX Open Gap Down %5 | Set Alert |
| ▼ GAP | $CGTX Open Gap Down %3 | Set Alert |
| ▼ GAP | $CGTX Open Gap Down %2 | Set Alert |
| ▼ BREAK | $CGTX Price Breaks 30 Days Low | Set Alert |
| ▼ BREAK | $CGTX Price Breaks 20 Days Low | Set Alert |
| ▼ BREAK | $CGTX Price Breaks 10 Days Low | Set Alert |
|
Wednesday, June 24, 2026 08:47 AM
The trial will evaluate once-daily 100 mg oral Zervimesine against a placebo in DLB patients experiencing hallucinations and delusions over a nine-month period. ・The company plans to present ...
|
|
Wednesday, June 24, 2026 05:46 AM
Cognition Therapeutics (NASDAQ:CGTX) shares gained 5% after the company announced that it had received written feedback from the U.S. Food and Drug Administration regarding the development pathway for ...
|
|
Wednesday, June 24, 2026 04:59 AM
Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -- Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/06/26 | 1.56 | 1.61 | 0.9697 | 1.02 | 11,675,726 |
| 23/06/26 | 1.62 | 1.75 | 1.55 | 1.65 | 1,326,793 |
| 22/06/26 | 1.455 | 1.76 | 1.45 | 1.68 | 4,022,234 |
| 18/06/26 | 1.50 | 1.50 | 1.39 | 1.45 | 1,271,134 |
| 17/06/26 | 1.29 | 1.475 | 1.25 | 1.42 | 2,326,611 |
| 16/06/26 | 1.22 | 1.30 | 1.194 | 1.26 | 1,075,132 |
| 15/06/26 | 1.26 | 1.29 | 1.21 | 1.21 | 856,737 |
| 12/06/26 | 1.225 | 1.23 | 1.185 | 1.21 | 440,364 |
| 11/06/26 | 1.14 | 1.22 | 1.1288 | 1.20 | 597,524 |
| 10/06/26 | 1.122 | 1.21 | 1.122 | 1.14 | 485,738 |
|
|
||||
|
|
||||
|
|